BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Argus Health
Healthtrust
Cerilliant
Baxter
Accenture
Express Scripts
US Army
Chinese Patent Office
Boehringer Ingelheim
McKesson

Generated: January 16, 2018

DrugPatentWatch Database Preview

LATISSE Drug Profile

« Back to Dashboard

Which patents cover Latisse, and what generic alternatives are available?

Latisse is a drug marketed by Allergan and is included in one NDA. There are eleven patents protecting this drug and one Paragraph IV challenge.

This drug has thirty-one patent family members in ten countries and three supplementary protection certificates in three countries.

The generic ingredient in LATISSE is bimatoprost. There are twelve drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the bimatoprost profile page.
Summary for LATISSE
International Patents:31
US Patents:11
Applicants:1
NDAs:1
Suppliers / Packagers: 1
Bulk Api Vendors: 42
Clinical Trials: 8
Patent Applications: 1,807
Drug Prices:see details
DailyMed Link:LATISSE at DailyMed
Drug patent expirations by year for LATISSE
Pharmacology for LATISSE
Ingredient-typeProstaglandins
Drug ClassProstaglandin Analog
Medical Subject Heading (MeSH) Categories for LATISSE

US Patents and Regulatory Information for LATISSE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Allergan LATISSE bimatoprost SOLUTION/DROPS;TOPICAL 022369-001 Dec 24, 2008 AT RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Allergan LATISSE bimatoprost SOLUTION/DROPS;TOPICAL 022369-001 Dec 24, 2008 AT RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Allergan LATISSE bimatoprost SOLUTION/DROPS;TOPICAL 022369-001 Dec 24, 2008 AT RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Allergan LATISSE bimatoprost SOLUTION/DROPS;TOPICAL 022369-001 Dec 24, 2008 AT RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Allergan LATISSE bimatoprost SOLUTION/DROPS;TOPICAL 022369-001 Dec 24, 2008 AT RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Allergan LATISSE bimatoprost SOLUTION/DROPS;TOPICAL 022369-001 Dec 24, 2008 AT RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Allergan LATISSE bimatoprost SOLUTION/DROPS;TOPICAL 022369-001 Dec 24, 2008 AT RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Allergan LATISSE bimatoprost SOLUTION/DROPS;TOPICAL 022369-001 Dec 24, 2008 AT RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Allergan LATISSE bimatoprost SOLUTION/DROPS;TOPICAL 022369-001 Dec 24, 2008 AT RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Allergan LATISSE bimatoprost SOLUTION/DROPS;TOPICAL 022369-001 Dec 24, 2008 AT RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for LATISSE
Drugname Dosage Strength RLD Submissiondate
➤ Subscribe Topical Solution 0.03% ➤ Subscribe 5/3/2010

Non-Orange Book US Patents for LATISSE

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,351,404 Method of enhancing hair growth ➤ Subscribe
8,298,518 Method of enhancing hair growth ➤ Subscribe
8,926,953 Method of enhancing hair growth ➤ Subscribe
7,388,029 Compositions and methods for treating hair loss using non-naturally occurring prostaglandins ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents for LATISSE

Supplementary Protection Certificates for LATISSE

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C0033 France ➤ Subscribe PRODUCT NAME: BIMATOPROST; NAT. REGISTRATION NO/DATE: EU/1/02/205/001 20020308; FIRST REGISTRATION:
00099 Netherlands ➤ Subscribe PRODUCT NAME: BIMATOPROST; NAT. REGISTRATION NO/DATE: EU/1/02/205/001 20020308; FIRST REGISTRATION: EU/1/02/205/001 20020308
C/GB02/035 United Kingdom ➤ Subscribe PRODUCT NAME: BIMATOPROST; REGISTERED: UK EU/1/02/205/001 20020308
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Baxter
Healthtrust
Chubb
Citi
Colorcon
Covington
Merck
Cerilliant

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot